Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Pingye Zhang"'
Autor:
Matthew Hellmann, Ying Cheng, Toshiaki Takahashi, Gilberto de Castro, M Catherine Pietanza, James Chih-Hsin Yang, Byoung Cho, Rosalyn Juergens, Mustafa Erman, Jessica Bauman, Paul Schwarzenberger, Pingye Zhang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/2116ff1baf5349cfbe8aac848a2def32
Autor:
Wei Shan, Jianwei Guo, Xuewei Mao, Yulei Zhang, Yikun Huang, Shuai Wang, Zixiao Li, Xia Meng, Pingye Zhang, Zhenzhou Wu, Qun Wang, Yaou Liu, Kunlun He, Yongjun Wang
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
Objective: Skull fractures caused by head trauma can lead to life-threatening complications. Hence, timely and accurate identification of fractures is of great importance. Therefore, this study aims to develop a deep learning system for automated ide
Externí odkaz:
https://doaj.org/article/c36d112adfb048a4ab84a726d1cec9a1
Publikováno v:
Frontiers in Aging Neuroscience, Vol 13 (2021)
This study aims to develop and validate an artificial intelligence model based on deep learning to predict early hematoma enlargement (HE) in patients with intracerebral hemorrhage. A total of 1,899 noncontrast computed tomography (NCCT) images of ce
Externí odkaz:
https://doaj.org/article/ee3ed7feb8e94be1a87d77be8919147f
Autor:
Man Jin, Pingye Zhang
Publikováno v:
Therapeutic Innovation & Regulatory Science.
Publikováno v:
Statistics in Biopharmaceutical Research. 14:523-531
In randomized clinical trials, there has been an increasing interest in identifying subgroups with heterogeneous responses to study treatment based on baseline patient characteristics. Even though the benefit risk assessment of any patient population
Autor:
Pingye Zhang, Man Jin
Publikováno v:
Statistical Methods in Medical Research. 30:1143-1151
Adaptive seamless Phase 2-3 design has been considered as one possible way to expedite development time for a drug program by allowing the expansion from an ongoing Phase 2 trial into a Phase 3 trial. Multiple endpoints are often tested when a regula
Publikováno v:
Contemporary Clinical Trials. 127:107119
Publikováno v:
Statistics in Medicine. 39:4133-4146
In randomized clinical trials with survival outcome, there has been an increasing interest in subgroup identification based on baseline genomic, proteomic markers or clinical characteristics. Some of the existing methods identify subgroups that benef
Publikováno v:
Contemporary Clinical Trials. 122:106931
In oncology, dose-finding studies are largely performed only in Phase I clinical trials and the maximum tolerated dose (MTD), a dose initially developed for systemic chemotherapies, is by default selected for the Phase 3 confirmatory trial. With the
Autor:
Balaji Venugopal, Jaroslav Hajek, Naomi B. Haas, Se Hoon Park, Mauricio Mahave, Pingye Zhang, David I. Quinn, Yen-Hwa Chang, Jae-Lyun Lee, Piotr Sawrycki, Thomas W. Ferguson, Kentaro Imai, Toni K. Choueiri, Thomas Powles, Stefan Symeonides, Antoine Thiery-Vuillemin, Piotr Tomczak, Jaqueline Willemann-Rogerio, Marine Gross-Goupil, Naveed Sarwar
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:Effective therapy to reduce risk of RCC relapse after surgery remains an unmet need. Adjuvant immune therapy is a potential strategy for these pts. The KEYNOTE-564 trial ...